01 Jun Former Blue Cross Blue Shield Executive and Private Equity Industry Leader Joins CrossBridge Advisory Board
Wayne, PA, March 10, 2020 – Lew Trowbridge, a nationally recognized healthcare industry executive and private equity adviser, has joined the Advisory Board CrossBridge. Lew is the Chairman and CEO of Canyon Road Advisors, LLC, a Santa Fe based consulting firm focused on helping companies use innovation to drive competitive advantage in the development of corporate strategy, with a primary focus in healthcare/health insurance. Prior to founding CRA, Lew was President and COO of Blue Cross Blue Shield of Nebraska (BCBSNE). Prior to being named president, he served as the Executive Vice President, Chief Financial Officer and Treasurer of the company. Under his leadership, BCBSNE developed one of the most extensive and financially successful private equity portfolios within the Blue Cross Blue Shield system.
Lew currently serves as an investor, board member and/or financial advisor for several healthcare related start-ups and health focused private equity funds. He serves as an adviser for Echo Health Ventures and Health Velocity Capital. He is adviser to Think Nebraska, LLC, a first of its kind, integrated care delivery enterprise with 46,000 patients and 24 independent primary care physicians; and Regional Health, a five hospital, 24 clinic care delivery system; and Genesys Innovations, LLC, an Omaha based company focusing on driving innovation and disruption for positive change in the health insurance payer space.
Lew was the co-founder of the Blue Investment Collaborative, a coalition of 10 like-minded Blue plans who meet regularly to discuss collaborative private equity. He also enjoyed a 22 year career as a partner with KPMG, with concentrations in M&A and financial services. Lew earned BBA and MBA degrees from the University of Cincinnati.
CrossBridge is an early-stage healthcare technology company, specializing in Software as a Service (SaaS) solutions that enable payers and healthcare providers to strive collaboratively for the best outcomes at the lowest cost for specialty chronic diseases – all while advancing the transition from fee-for-service to Value Based Payments (VBP).